期刊
ANNUAL REVIEW OF MEDICINE, VOL 64
卷 64, 期 -, 页码 131-144出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-112211-154330
关键词
cyclooxygenase; prostaglandins; nonsteroidal anti-inflammatory drugs (NSAIDs); chemoprevention
资金
- NCI NIH HHS [P01 CA77839] Funding Source: Medline
- NIDDK NIH HHS [R01 DK 62112, R37 DK047297, R37 DK47297] Funding Source: Medline
- PHS HHS [RP100960] Funding Source: Medline
A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet, and lifestyle are key risk factors for colorectal cancer (CRC). Prevention of CRC has long been considered a plausible approach for the population and individuals at high risk for developing this disease. A significant effort has been made in the development of novel drugs for both prevention and treatment over the past two decades. This review highlights recent advances in our understanding of the role of nonsteroidal anti-inflammatory drugs in CRC prevention and adjuvant treatment. Moreover, we focus on the molecular mechanisms underlying the antitumor effects of these drugs in CRC. The knowledge of how anti-inflammatory agents inhibit cancer formation and progression may provide a rationale for the development of more effective chemopreventive and chemotherapeutic agents with less toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据